Patents by Inventor Susie Miki Harris

Susie Miki Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREM2 ANTIGEN BINDING PROTEINS AND USES THEREOF
    Publication number: 20220204611
    Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
    Type: Application
    Filed: September 28, 2021
    Publication date: June 30, 2022
    Inventors: Ian N. FOLTZ, Shilpa SAMBASHIVAN, Irwin CHEN, Susie Miki HARRIS, Dora TOLEDO WARSHAVIAK, Ian DRIVER, Daniel LU
  • Anti-human TREM2 antibodies and uses thereof
    Patent number: 11186636
    Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 30, 2021
    Assignee: AMGEN INC.
    Inventors: Ian Foltz, Shilpa Sambashivan, Irwin Chen, Susie Miki Harris, Dora Toledo Warshaviak, Ian Driver, Daniel Lu
  • TREM2 Antigen Binding Proteins And Uses Thereof
    Publication number: 20210054069
    Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
    Type: Application
    Filed: April 20, 2018
    Publication date: February 25, 2021
    Applicant: AMGEN INC.
    Inventors: Ian Foltz, Shilpa Sambashivan, Irwin Chen, Susie Miki Harris, Dora Toledo Warshaviak, Ian Driver, Daniel Lu
  • Human FGF receptor and ?-Klotho binding proteins
    Patent number: 9517264
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: December 13, 2016
    Assignee: AMGEN INC.
    Inventors: Roger Fachini, Ian Foltz, Seog Joon Han, Susie Miki Harris, Shaw-Fen Sylvia Hu, Chadwick Terence King, Yang Li, Ji Lu, Mark Leo Michaels, Jeonghoon Sun
  • HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS
    Publication number: 20130129725
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: April 13, 2011
    Publication date: May 23, 2013
    Inventors: Roger Fachínì, Ian Foltz, Seog Joon Han, Susie Miki Harris, Shaw-Fen Sylvia Hu, Chadwick Terence King, Yang Li, Ji Lu, Mark Leo Michaels, Jeonghoon Sun